Characteristic | All cases | HDAC 1 low (IRS 0–4) | HDAC 1 intermediate (IRS 6–8) | HDAC 1 high (IRS 9–12) | P-valueχ 2-test for trends |
---|---|---|---|---|---|
All cases | 208 (100%) | 71 (34.1%) | 69 (33.2%) | 68 (32.7%) | -- |
Histological type | 0.17 | ||||
Ductal carcinoma/Other | 176 (100%) | 62 (35.2%) | 60 (34.1%) | 54 (30.7%) | |
Lobular carcinoma | 28 (100%) | 7 (25%) | 9 (32.1%) | 12 (42.9%) | |
Histological grade | 0.89 | ||||
G1 | 61 (100%) | 24 (39.3%) | 20 (32.8%) | 17 (27.9%) | |
G2 | 90 (100%) | 25 (27.8%) | 28 (31.1%) | 37 (41.1%) | |
G3 | 53 (100%) | 20 (37.8%) | 21 (39.6%) | 12 (22.6%) | |
Nodal status | 0.23 | ||||
negative | 129 (100%) | 48 (37.2%) | 42 (32.6%) | 39 (30.2%) | |
positive | 67 (100%) | 18 (26.9%) | 26 (38.8%) | 23 (34.3%) | |
pT-Stage | 0.88 | ||||
pT1 | 116 (100%) | 41 (35.3%) | 37 (31.9%) | 38 (32.8%) | |
pT2/pT3 | 78 (100%) | 23 (29.5%) | 30 (38.5%) | 25 (32%) | |
pT4 | 9 (100%) | 4 (44.4%) | 2 (22.2%) | 3 (33.4%) | |
Hormone receptor status | <0.001* | ||||
Hormone receptor positive | 162 (100%) | 46 (28.4%) | 54 (33.3%) | 62 (38.3%) | |
Hormone receptor negative | 41 (100%) | 22 (53.7%) | 15 (36.6%) | 4 (9.7%) | |
HER2 status | 0.71 | ||||
negative | 175 (100%) | 60 (34.3%) | 58 (33.1%) | 57 (32.6%) | |
positive | 25 (100%) | 9 (36%) | 9 (36%) | 7 (28%) |